Dolby Laboratories (NYSE:DLB – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 4.300-4.450 for the period, compared to the consensus EPS estimate of 4.110. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.4 billion. Dolby Laboratories also updated its Q3 2026 guidance to 0.560-0.710 EPS.
Dolby Laboratories Price Performance
Shares of DLB stock traded down $6.66 on Friday, reaching $57.48. 2,137,252 shares of the company were exchanged, compared to its average volume of 482,138. The company has a market cap of $5.49 billion, a price-to-earnings ratio of 23.18 and a beta of 0.86. The company has a 50-day moving average of $62.58 and a 200-day moving average of $64.55. Dolby Laboratories has a one year low of $55.73 and a one year high of $78.28.
Dolby Laboratories (NYSE:DLB – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The electronics maker reported $1.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.06. Dolby Laboratories had a net margin of 17.85% and a return on equity of 11.48%. The company had revenue of $395.63 million for the quarter, compared to analysts’ expectations of $385.80 million. During the same quarter in the prior year, the firm earned $1.34 EPS. The business’s revenue was up 7.0% on a year-over-year basis. Dolby Laboratories has set its FY 2026 guidance at 4.300-4.450 EPS and its Q3 2026 guidance at 0.560-0.710 EPS. As a group, sell-side analysts predict that Dolby Laboratories will post 3.17 EPS for the current year.
Dolby Laboratories Dividend Announcement
Analyst Upgrades and Downgrades
DLB has been the topic of several recent research reports. Barrington Research reaffirmed an “outperform” rating and issued a $90.00 price target on shares of Dolby Laboratories in a research report on Monday, April 27th. Rosenblatt Securities reaffirmed a “buy” rating and issued a $85.00 price target on shares of Dolby Laboratories in a research report on Friday, January 30th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Dolby Laboratories in a research report on Friday, March 27th. Finally, Wall Street Zen cut shares of Dolby Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $90.75.
View Our Latest Report on Dolby Laboratories
Insider Activity
In other Dolby Laboratories news, CAO Ryan Nicholson sold 2,667 shares of the stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $66.38, for a total value of $177,035.46. Following the completion of the sale, the chief accounting officer owned 36,956 shares in the company, valued at approximately $2,453,139.28. This trade represents a 6.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Shriram Revankar sold 3,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $66.14, for a total transaction of $198,420.00. Following the completion of the sale, the senior vice president owned 83,218 shares of the company’s stock, valued at approximately $5,504,038.52. This trade represents a 3.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 37.93% of the company’s stock.
More Dolby Laboratories News
Here are the key news stories impacting Dolby Laboratories this week:
- Positive Sentiment: Q2 results topped Street estimates — Dolby reported EPS of $1.37 and revenue of roughly $395.6M, driven by licensing strength, higher broadcast demand and continued Dolby Atmos adoption. This topline beat supports near‑term growth narratives. Dolby Q2 Earnings Top Estimates on Licensing Strength, Revenues Up Y/Y
- Positive Sentiment: Management raised FY‑2026 outlook — Dolby lifted full‑year EPS guidance to $4.30–$4.45 (above consensus) and gave a revenue range that implies mid‑single‑digit growth for the year, supporting longer‑term earnings expectations. Dolby Laboratories Reports Second Quarter 2026 Financial Results
- Neutral Sentiment: Quarterly dividend declared — Dolby set a $0.36 quarterly dividend (yield ~2.5%), payable May 20 with an ex‑dividend date of May 12. This supports income investors but is expected and not a surprise.
- Neutral Sentiment: Earnings materials available — The full earnings release and call transcript are published for more detail on segment trends, customer wins and product adoption; useful for digging into assumptions behind guidance. Dolby Q2 2026 Earnings Call Transcript
- Negative Sentiment: Weak Q3 guidance drove the sell‑off — Dolby guided Q3 EPS of $0.56–$0.71 and revenue of $295–$325M, both materially below consensus (Q3 revenue guidance ~ $343M and EPS ~ $0.92), signaling near‑term demand variability and prompting investor concern.
- Negative Sentiment: Cash‑flow and other operational flags — Third‑party summaries highlighted a sharp drop in operating cash flow year‑over‑year and a modest decline in cash balances, raising questions about near‑term cash generation despite GAAP profitability. Dolby Laboratories (DLB) Stock Falls on Q2 2026 Earnings
- Negative Sentiment: Insider and institutional activity noted — Recent reporting flagged substantial insider selling and some large institutional position reductions, which can add downward pressure on sentiment if sustained. Dolby Laboratories (DLB) Stock Falls on Q2 2026 Earnings
Institutional Investors Weigh In On Dolby Laboratories
Large investors have recently modified their holdings of the stock. Aquatic Capital Management LLC purchased a new stake in shares of Dolby Laboratories during the 3rd quarter worth approximately $56,000. iSAM Funds UK Ltd purchased a new stake in shares of Dolby Laboratories during the 3rd quarter worth approximately $68,000. Quarry LP increased its stake in shares of Dolby Laboratories by 1,486.7% during the 4th quarter. Quarry LP now owns 1,190 shares of the electronics maker’s stock worth $76,000 after purchasing an additional 1,115 shares during the last quarter. Advisory Services Network LLC purchased a new stake in shares of Dolby Laboratories during the 3rd quarter worth approximately $102,000. Finally, US Bancorp DE increased its stake in shares of Dolby Laboratories by 31.3% during the 3rd quarter. US Bancorp DE now owns 1,429 shares of the electronics maker’s stock worth $103,000 after purchasing an additional 341 shares during the last quarter. Hedge funds and other institutional investors own 58.56% of the company’s stock.
About Dolby Laboratories
Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company’s core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby’s licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.
Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.
Featured Articles
Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
